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1. Introduction 
Inflammatory bowel diseases (IBD), including Crohn’s disease and ulcerative colitis (UC), 
are complex disorders characterized by chronic, local and systemic inflammation and 
spontaneously relapsing course. The causes of these diseases are unknown, however they  
display genetic and environmental components and  appear to be immunologically 
mediated in part by enteric microbiota (Baumgart & Carding, 2007). 
There are convincing evidences that IBD are diseases of immunological 
hyperresponsiveness within the mucosa. Immunological reactions may be directed against 
luminal bacteria and their products normally present in the intestine (Sartor, 2006). 
Alternatively, mucosal inflammation in IBD might represent an immune response against 
unusual antigens such as environmental factors and/or epithelial HLA halotypes. The 
initiating events may be nonspecific and induce transient injury. The normal response is 
suppression of inflammation, but genetically susceptible host amplifies the inflammatory 
response. The activation of intestinal  T helper cells (TH1, TH2 and TH17) play a pivotal role 
in experimental and human IBD because they modulate of the response to enteric 
microbiota and autoimmunity which is probably critical to IBD chronicity. Crohn’s disease 
is TH1 and TH17 related disorder with local over-production of  interleukin – 2 (IL-2), 
interpheron Ǆ (INFǄ), IL - 12, and IL-23, whereas in UC it is apparent activation of TH2 
lymphocyte cytokine profile, mostly IL-4 and IL-10 as well as  IL-13 by natural killer T cells.  
Interaction of activated T cells with effector cells (macrophages and neutrophils) leads to 
release of cytokines, eicosanoids and activation of complement cascade and coagulation and 
kallikrein - kinin systems which cause tissue injury. Many cytokines including interleukin 1 
(IL-1), tumor necrosis factor (TNF) and IL-8 are increased in both active UC and Crohn’s 
disease. The tissue levels of arachidonic acid metabolities; prostaglandins,leukotrienes and 
thromboxanes correlate with gross and histological evidence of intestinal inflammation in 
IBD.  The activation of coagulation has been recognized as important component of the 
inflammatory response in both Crohn’s disease and UC, and also is significant in 
progression and possibly pathogenesis of these entities (Danese et al., 2007). A significance 
the kallikrein – kinin system in human IBD is still uncertain although in animal IBD  models 
kallikreins and kinins  have been documented  in part to mediate intestinal and  systemic 
inflammation. There are two types of kallikreins, plasma and tissue; both serine protease 
www.intechopen.com
 
Ulcerative Colitis – Epidemiology, Pathogenesis and Complications 
 
174 
enzymes may cleave kininogens to release kinins, a potent inflammatory mediators (Bhoola 
et al., 1992).   
2. Plasma kallikrein-kininogen system 
A single gene codes for plasma kallikrein, which is synthetized in the liver. The plasma 
kallikrein-kinin system is comprised of factor XII (Hageman factor) factor XI (initiator of 
intrinsic coagulation pathway), plasma prekallikrein, and high molecular weight kininogen 
(HK). Activation of the plasma kallikrein – kinin system (known also as the contact system) 
is initiated by autoactivation of factor XII yielding factor XIIa, which, in turn, activates 
prekallikrein to kallikrein. Kallikrein can cleave its own heavy chain (56 kDa) at Lys140- 
Ala141 to form two fragments of 28kDa and 18 kDa. Kallikrein can also react with C1-
inhibitor (C1-INH) to form an inactive complex (Mr 190 kDa) (Campbell, 2001; Colman, 2006 
c). Plasma kallikrein cleaves HK to release bradykinin, and enhances plasmin formation by 
activating prourokinase to urokinase (Ichinose et al., 1986). The major regulator of activation 
of the contact system is the plasma protease inhibitor, C1-INH, which inhibits activated 
factor XIIa, kallikrein, and factor XIa. In addition, alfa- 2 macroglobulin is an important 
inhibitor of kallikrein and a 1-antitrypsin for factor XIa. Plasma kallikrein exists as a 
zymogen, prekalliktein, 75% of which circulates in the blood in a noncovalent complex with 
HK. HK is multifunctional protein, ǃ-globulin, with a plasma concentration about 80 µg/ml. 
HK is consisted of 6 domains divided into heavy chain (HK domains 1-3), and light chain 
(HK domains 5-6), linked by domain 4 which contains the sequence of bradykinin. Low 
molecular weight kininogen (LK) is present in plasma and various tissues. LK is ǃ-globulin 
with a plasma concentration of 220 µg/ml, it has identical domain 1 through domain 4 of 
HK. However LK domain 5 is completely different from HK and domain 6 is lacking 
(Colman, 2006). Cleavage of HK by plasma kallikrein generates proinflammatory and 
proangiogenic bradykinin, and forming biologically active kininogen fragment HKa. 
Products of this pathway induce a variety of inflammatory events. Kallikrein is also 
implicated in neutrophil activation with release of lysosomal enzymes, such as elastase 
(Wachtfogelet al., 1983), as well as potentiation of superoxide formation (Schapira et al., 
1982). In addition, plasma kallikrein and factor XII fragments may activate the alternative 
and classical complement pathways, respectively. Recent studies shown that HKa may 
stimulate in vitro secretion of cytokines; IL-1 ǃ, IL-6, and TNF and chemokines from 
monocytes through signaling pathways by urokinase –type plasminogen receptor, integrin 
ǂ-1 ǃ2 (MAC-1) receptor, and complement protein C1q receptor (Khan et al., 2006). IL1- ǃ 
release is localized to domain – 3 and domain -5 of HK. In addition HK and HKa have an-
adhesive properties and HKa and domain 5 of HK inhibit angiogenesis (Colman 2006 b).  
3. Tissue kallikreins and kinins 
Tissue and plasma kallikreins differ in their molecular weight, isoelectric point, 
immunological properties, and substrate preference. Tissue kallikreins is a member of a 
multigene family that shows different patterns of tissue specific gene expression ((Clements 
et al., 1992). Under physiological conditions, tissue kallikrein is present in the highest 
concentration in exocrine glands, mostly in salivary glands and pancreas (Wolf et al., 1998). 
In salivary glands tissue kallikrein occurs in active form, while in pancreas is present as 
proenzym.Both active and precursor forms are present in excretory product such as urine 
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and sweat. Kallikrein purified from both rat and human colon was found to be 
biochemically similar, if not identical, to tissue kallikrein for salivary gland and pancreas 
(Chen et al., 1995). Although HK is a better substrate for plasma kallikrein to release 
bradykinin and low molecular weight kininogen (LK) is better substrate for tissue kallikrein 
liberates kallidyn (Lys – bradykin), both are substrate for both plasma and tissue kallikreins. 
Kallistatin present in tissues and plasma is a main inhibitor of tissue kallikrein (Chao et al., 
1996). Plasma kallikrein releases nonapeptide, bradykinin from HK, while tissue and 
glandular kallikreins liberates decapeptide, kallidyn (Lys–bradykinin) from LK. Kallidyn is 
rapidly converted to bradykinin by aminopeptidase. Bradykinin has short half life – 30 
second in circulation. Kinins are rapidly destroyed by kininases, which are present in blood 
and in tissues. Removal of its C-terminal arginine by kininase I (carboxypeptidase N) forms 
an active metabolite des-Arg 9 bradykinin, which has a half life approximately 2 hours. 
Kininase II, known also as angiotensin converting enzyme (ACE) to remove the COOH – 
terminal peptides metabolizes kinins to their inactive forms (Bhoola et al., 1992). The final 
metabolite of bradyninin and des-Arg9-bradykinin is bradykinin 1-5. T-kinins forming by 
 
 
Fig. 1. Potential significance of plasma kallikrein- kinin system in inflammation. 
PG-PS: peptidoglycan – polysaccharide; LPS: lipopolysaccharide; EC: endothelial cell; M: 
monocyte; N: neutrophil, HK: high molecular weight kininogen; TF: tissue factor; NO: nitric 
oxide, uPAR: urokinase plasminogen activated receptor. Solid arrows designate activation 
or cofactor amplification, dashed arrows designate conversion, and open arrows indicate 
release, expression, or synergistic properties 
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cleavage T – kininogen were exclusively identified  in rats (Okamoto et al., 1993). 
Bradykinin  and kallidin and theirs active metabolite, des-Arg9-bradykinin and Lys - des-
Arg9-bradykinin respectively bind to  two transmembran G protein - coupled receptors 
designated as bradykinin receptor - 2 (B2R) and bradykinin receptor – 1 (B1R). BR2 are 
constitutive mainly expressed in endothelial cells, stimulated by bradykinin to release nitric 
oxide and other negative regulators of  smooth muscle tone and platelet function. However 
BR2 might also be upregulated in the acute phase of inflammation (Calixto et al., 2003; 
Moreau et al., 2005). B1R are inducible following tissue injury or after treatment with 
bacterial endotoxins or inflammatory cytokines such as interleukin -1 ǃ (IL1- ǃ) or tumor 
necrosis factor – ǂ (TNF- ǂ). Cytokine-induced B1R expression is mediated by nuclear factor 
– κ ǃ (NF- κ ǃ) and specific MAP – kinase pathways (mainly p38 and JNK) (Ni et al., 1998).  
 
 
Fig. 2. Potential role of intestinal tissue kallikrein – kinin system in inflammatory bowel 
disease. Solid arrows designate activation, dashed arrows designate conversion, open 
arrows indicate induction, and interrupted lines indicate blockade. B2 and B1: kinin 
receptors; NO: nitric oxide; ITK: intestinal tissue kallikrein 
4. Plasma kallikrein – kinin system in IBD 
In the past two decades, the role of plasma kallikrein- kinin system in experimental and 
human sepsis (Pixley et al., 1995), and other acute inflammatory states including Rocky 
Mountains spotted fever (Rao et al., 1988), human experimental endotoxemia (DeLa Cadena 
et al., 1998), and acute pancreatitis has been well delineated . In 1990s we have developed 
experimental model of enterocolitis induced by bacterial cell wall polymer peptidoglycan – 
polysaccharide from group A streptococci (PG – APS) ( Sartor at al., 1996). Female Lewis 
rats, the highest responders injected intramurally by PG-APS developed acute intestinal 
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inflammation that peaks 1-2 days after PG – APS injection, gradually decreases over the next 
10 days and spontaneously reactivates beginning on day 14, accompanied by peripheral 
erosive arthritis, granulomatous hepatitis, normochromic anemia and leukocytosis, with 
histological findings of intestinal fibrosis and granulomas. Acute intestinal inflammation 
developed in all rat strains investigated, but chronic, transmural, granulomatous 
reactivation only in genetically susceptible Lewis rats, but not in Buffalo or Fisher rats. This 
model  has unique features resembling Crohn’s disease. Inflammation induced by APG – PS, 
similar to human IBD is mediated by large number of inflammatory cascades and liberation 
of soluble mediators including cytokines, prostanoids and activation of the kallikrein-kinin 
system. We have developed a specific plasma kallikrein inhibitor (P8720) to evaluate a direct 
relationship between the plasma kallikrien- kinin activation and inflammatory changes. 
Treatment with the specific, oral plasma kallikrein inhibitor, P8720, in the acute and chronic 
granulomatous phase of enterocolitis in Lewis rat decreased the increase of gut gross and 
histological score and systemic inflammation, and prevented the decrease of plasma FXI and 
HK. ( Stadnicki et al., 1996; Stadnicki et al., 1998 b). This activation is not specific for PG-APS 
since it has been demonstrated that it can also be induced in Lewis rats chronic enrerocolitis 
model- induced by indomethacin (Stadnicki et al., 1998 c). Looking for a functional 
mechanism involved in selective activation of the kallikrein- kinin system in genetically 
susceptible Lewis rats, we found that HK cleavage and yielding bradykinin by plasma 
kallikren was faster in Lewis rat plasma than in Buffalo rat plasma and Fisher rat plasma 
(Sartor at al., 1996). It has been found that  a single point mutation at nucleotide 1586 
translating  from Ser511 (Buffalo and Fisher) to Asn511 (Lewis) is associated with N- 
glycolization indicating that this molecular alteration may be one contributing factor 
resulting in chronic reactive colitis in Lewis rats (Isordia Salas et al., 2003). Administration of  
PG – APS causes a similar biological response as triggered by endotoxins (LPS) which is 
detectable in plasma in most IBD patients during relapse (Gardiner et al 1995) indicating 
that both bacterial products act  through similar the innate immunity activation, cytokines 
and mediators. Later it has been demonstrated that in patients with UC in active disease 
phase (but not in inactive UC) there was moderate activation of this system as significant 
decrease of plasma prekallikrein, HK and functional levels of C1 – inhibitor, and in some 
patients formation of kallikrein – inhibitor complexes on Western blot  (Stadnicki et al., 
1997). However in Crohn’s disease study it not been found these chances in plasma of 
patients probably due the high plasma levels of C1 – inhibitor (Devani et al., 2002). 
5. Intestinal tissue kallikrein – kinin system in IBD 
5.1 Intestinal tissue kallikrein 
The presence of kallikrein in gastrointestinal tract has been observed since 1960s (Schachter 
et al., 1986; Werle, 1960) but little has been done to evaluate its role in IBD. Long time ago 
only one study (Zeitlin & Smith, 1973) reported the presence of tissue kallikrein in normal 
human colon and a higher concentration in the inflamed colon of patients with UC. In rat 
model of PG – APS stimulated chronic inflammation we have shown that the normal 
location of ITK was the goblet cells and substantial amounts of ITK were present in the 
macrophages of the granulomas found in the submucosa indicating that ITK is present at 
the site of inflammation (Stadnicki et al., 1998 a). ITK concentrations were markedly reduced 
in the inflamed cecum as compared with the normal, but ITK protein concentration was 
associated with unchanged ITK mRNA levels, which indicated that its reduction was not 
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due to suppression of its gene expression. Further evidence that inflamed intestinal tissue 
cells had secreted ITK to a greater extend that normal it has got from in vitro culture study 
showing marked IIK decrease in supernatant from in vitro cultures of inflamed intestine. In 
addition a potent tissue kallikrein inhibitor, kallikrein binding protein in the rat (whose 
human homolog is kallistatin) was decreased in rat plasma during inflammation suggesting 
release ITK into plasma. In human studies we have demonstrated that ITK was in goblet 
cells in normal and inflamed human colon which was in agreement with previous findings 
in rats (Stadnicki et al., 2003). Again ITK levels were significantly decreased in inflamed 
intestinal tissue from patients with IBD compared to normal controls consistent with its 
secretion in vivo. The kallistatin, a specific inhibitor, naturally occurring serine protein 
inhibitor (serpin) of human tissue kallikrein, was localized to epithelial cells. Kallistatin 
apparently colocalizes within ITK in the macrophages within the granulomas. It has been 
shown also decreased plasma levels of kallistatin in IBD patients similarly like kallikrein 
binding protein in rat enterocolitis which indicated that the secretion of ITK results in active 
form since kallistatin only steichometrically combines with enzymatically active tissue 
kallikrein (Xiong et al., 1992). Other study indicated that the goblet cells may have a more 
active role in the regulation of intestinal homeostasis and immunologic processes by 
interaction this other cells such as macrophages and lymphocytes (Lichtenstein, 2000). The  
factors which determine ITK secretion and activation are still not defined. It is known that 
inactive tissue prokallikrein can be activated by trypsin, plasmin, or even plasma kallikrein 
(Bhoola et al., 1992). Such enzymes could enter the intestinal space through several routes: 
by transudation of plasma or release from inflammatory cells. Interestingly a 
proinflammatory effect of ITK in the intestine are due to macrophage production and 
secretion. It has been demonstrated tissue kallikrein on human blood neutrophils, but did 
not detect the enzyme in monocytes (Figueroa et al., 1989). It is possible that tissue kallikrein 
is only expressed in stimulated monocytes or macrophages, as is the case for tissue factor 
(Gregory & Edgington, 1985). However, luminal ITK may enter the inflamed mucosa due to 
enhanced permeability, where it could hydrolyze growth factors and peptides which could 
act on the epithelial mucosa cells. In fact it has been demonstrated that ITK 
immunoreactivity was significantly weaker in gobled cells in both Crohn’s disease and 
ulcerative colitis patients, but with strong reactivity in intestinal interstitium of IBD patients 
(Devani et al., 2005). ITK can cleave low kininogen which  is present in intestine as well as 
both LK and HK, which are present in plasma and likely to be present in the protein – rich 
exudates of the inflamed intestine. Apart from its kininogenase activity, tissue kallikrein has 
been implicated in the processing of grow factors and peptide hormones. Tissue kallikrein 
hydrolyze vasoactive intestinal peptide and procollagenase in vitro (Techesche et al., 1983). 
If these reactions take place in IBD, ITK may influence intestinal motility, secretion and 
connective tissue metabolism. Moreover in experimental and human IBD the number of 
mast cells and mast cells tryptase expression are increased in the colonic mucosa and 
submucosa (He, 2004). In addition, activated basophils and mast cells contain and can release 
kallikrein as an additional local intestinal source of tissue kallikrein (Min & Paul, 2008). 
5.2 Kinins and kinin receptors in IBD 
Almost fifty years ago it has been  demonstrated  that bradykinin was able to evoke cardinal 
signs of inflammation (Lewis, 1964).  In addition in chronic inflammation B1R seems to be 
important in neutrophil accumulation in inflamed tissue (McLean et al., 2000). Both B1R and 
B2R are involved in onset and maintenance of nociceptive alterations and inflammatory 
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pain perceptions (Drey, 1997; Rupniak et al., 1997). Research on involvement of B2Rs in 
inflammatory states has progressed more quickly than that on B1Rs, and it was favored by 
the systematic development of selective peptidic B2R antagonists by the pharmaceutical 
companies, at this time. Thus we described B2Rs distribution in PG – APS induced model of 
granulomatous enterocolitis in intestinal layer showing B2R in epithelial cells, smooth 
muscle cells, and in serosa (Stadnicki et al., 1998 c).  In this model a specific bradykinin BR2 
antagonist (HOE – 140) attenuated arthritis but exhibited only minimal preventive effect on 
enterocolitis suggesting that kinin stimulation via B2R was a more important in arthritis 
than of enterocolitis (Stadnicki et al., 1999).  In dextran sulfate (DDS) - induced colitis model 
in mice a selective B2R antagonist  suppressed shortening of the large intestine (Arai et al., 
1999), which was in agreement with future results indicated that intestinal contraction was 
regulated by B2R (Hara et al., 2007), however  demonstrated only limited effect in intestinal 
inflammatory lesions. Later in human studies we demonstrated the increase in the ratio of 
B1R to B2R gene expression in relation to the degree of intestinal inflammation, and 
visualized both B1R and B2R in normal as well as inflammatory human colon and ileum 
(Stadnicki et al., 2005). B2R protein was normally present in the apices of enterocytes in the 
basal area and intracellularly in inflammatory tissue.  In contrast, B1R protein was found in 
the basal area of enterocytes in normal intestine, but in the apical portion of enterocytes in 
inflamed tissue.  B1R protein was significantly increased in both active UC and Crohn’s 
disease intestines compared to controls. In addition B1R was observed in the nerve of the 
colonic submucosa. Importantly B1R but not B2 was present in macrophages inside 
granulomas of Crohn’s intestine. The total level of B1R was significantly higher in 
enterocytes of patients with active phase of UC as well as in Crohn’s disease as compared 
with controls. Recent studies have demonstrated that the B2R receptor may be recycled 
several times in the same enterocytes after internalization (Bachvarov et al., 2001; Souza et 
al., 2007).  This process was supported by the appearance of B2R intracellularly in some 
enterocytes in UC intestine. In contrast B1R normally do not internalize following agonist 
stimulation, but they seem to translocate and aggregate after agonist binding, probably to 
facilitate the amplification of B1 receptor mediated responses (Sabourin et al., 2002). Taken 
together the results strongly indicated that the B1R receptor is a major structural 
background for kinins function in human IBD. Kinins are involved in intestinal glucose and 
electrolyte transport and local blood flow under normal conditions. However in intestine, 
kinins may be more important as pathophysiological mediators. It has been shown that 
bradykinin produces 2 – 4 – fold greater concentration of prostanoids in animals with 
experimental colitis than in normal controls, which may contribute to the increased 
intestinal secretion of chloride (Zipser et al. 1985). Bradykinin – induced chloride secretion 
by the guinea pig ileum occurs by direct binding of the ligand to its receptor (Maning et al., 
1982). It has been shown that both inducible B1R and constitutive B2R mediate the ion 
transport in intestinal epithelium (Cuthbert, 2001). The secretion of chloride into the lumen 
is accompanied with natrium secretion and in turn water, thus leading to secretory diarrhea, 
and this effect of kinins is much prostaglandin-independent.  In relation to IBD kinins may 
act on endothelial cells, smooth muscle cells, epithelial cells, and fibroblasts, which stimulate 
cell response through G proteins - coupled kinin receptors. By opening the tight junctions 
between endothelial cells, kinins can increase capillary permeability (Gaginella & Kachur, 
1989). Kinins may stimulate though B2R inflammatory cell adhesion molecules, and white 
blood cells migration. Subsequently B1R stimulation promote more cell adhesion molecules, 
and cells influx mainly neutrophils into extravascular comparment(McLean et al., 2003; 
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Ulbrich et al., 2000). Kinins may act as mitogens to increase DNA synthesis, thereby 
promoting cell proliferation. The ability of kinins to stimulate fibroblast proliferation may 
contribute to fibrosis in chronic intestinal inflammation (Marceau et al., 1986). Kinins may 
stimulate macrophage release of IL-1 and TNF – ǂ (Tiffany & Burch, 1989). This effect is 
probably mediated by stimulation of the RB1, since a specific RB1 antagonist block kinin- 
induced cytokine release. In human study it has been  demonstrated  a positive staining for 
TK, kallistatin and the B1R (but not the B2R) in macrophages forming granuloma and for 
B1R in plasmocytes in the border of granulomas which emphasizes the close relationship 
between the immune responses important in IBD and the inflammatory mediators including 
the ITK – kinins. Kinins may also evoke pain by stimulating sensory nerves to mechanical 
stimuli and other chemical mediators and, in turn, causes hyperalgesia (Drey, 1997). The 
role of B1R and its agonists in inflammatory pain has been shown in animals (Rupniak et al., 
1997). In addition, bradykinin accelerates mucin discharge from goblet cells (Stanley & 
Philips, 1994). Although it is not know if ITK is co – secreted with mucin after bradykinin 
action, it raises the possibility of positive feedback loop between local ITK release and 
bradykinin generation. In addition, it has been demonstrated a B1R polymorphism in 
human IBD, but its clinical significance remains unknown (Bachvarov at al., 1998).  The 
recent experimental study  investigated the role of BR1s in TNBS - induced mouse model of 
colitis showing that  that selective, orally active, non - peptide B1R antagonist SSR240612 
markedly reduced TNBS – induced colitis e.g. intestinal tissue damage and neutrophil influx 
(Hara et al., 2008).  Importantly this study clarified evidence  that TNF – ǂ may upregulate 
B1R expression in TNBS colitis model suggesting that anti- TNF- ǂ monoclonal antibodies 
may  in part  modulate IBD by regulation of BR1 expression. It should be noted that kinins 
are implicated in the regulation of blood pressure, sodium homeostasis and the 
cardioprotective effect of preconditioning (Chao et al., 2004). Angiotensin- converting 
enzyme (kininase II) inhibition increase blood levels of bradykinin and kallidin peptides 
(Colman et al., 2006 c). Thus, the potentially salutary role of kinins in the circulation not 
encourage systemic administration of B1R antagonist. In fact commonly used ACE 
inhibitors are cardioprotective in part by elevating bradykinin, and thus increasing nitric 
oxide as well as decreasing angiotensin II formation (Colman et al., 2006c). Kinins have been 
demonstrated to stimulate synthesis of eicosanoids, nitric oxide and cytokines by white 
blood cells, endothelial cells and epithelial cells, and promote adhesion molecule – 
neutrophil cascade known to be important in IBD. A selective B1R receptor antagonist may 
have potential in therapeutic trial. It has been postulated that topical drug delivery to 
intestine as for 5 – ASA compounds to avoid side effect may be appropriate for the 
management of IBD (Marceau & Regoli, 2008). In fact the levels of kinin peptides in tissue 
were higher than in blood suggesting the primary tissue localization of the kallikrein – kinin 
system (Campbell, 2001). Nevertheless it seems that the contact system plays an important 
role in many inflammatory cascades by activation of the complement system, enhances 
liberation of prostanoids and cytokines, and specifically interacts with coagulation, 
fibrinolytic components and platelets. 
6. Hemostatic alterations in IBD 
The current model of coagulation in vivo emphasizes tissue factor as initiator of coagulation 
activation, underlines main role of thrombin in amplification of coagulation, and the 
interaction of coagulation factors with blood cells and endothelial cells (Hoffman & Monroe, 
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2007). Activated cells, especially platelets are critical in amplification and propagation 
phases providing a negatively – charged phosfolipid surface on which clotting reactions 
may take place. In IBD the coagulation system may be activated following cellular injury 
mainly through the extrinsic pathway. Tissue factor, a potent trigger of coagulation, 
functions as a monocyte and endothelia cell  receptor which binds factor VII and facilitates 
activation of both factor IX and factor X. Activated factor X (FXa), Ca ++ , activated factor V 
(FVa), and platelet phospholipid form the prothrombinase complex that cleaves 
prothrombin, producing thrombin and liberating a prothrombin fragment, F1 + 2. Thrombin 
hydrolyzes fibrinogen forming fibrin, which is cross-linked by activated factor XIII. Cross-
linked fibrin is then degraded by plasmin with the liberation of D-dimer and other 
degradation products. Factor XII converts the zymogen, factor XI, to an active enzyme, 
factor XIa, which, in turn, converts factor IX to factor IXa, thereby activating the intrinsic 
pathway of coagulation. (Clolman,  2006 a).  
 
 
Fig. 3. Diagram of main pathways of coagulation. EC is endothelial cell, M is monocyte, PL 
is platelet, F1+2 is prothrombin fragment, FPA is fibrinopeptide A, ǃTG is ǃ- 
thromboglobulin, TF is tissue factor. Solid arrows designate activation or cleavage, dashed 
arrows conversion, and open arrows indicate release, expression, or synergistic properties 
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6.1 Systemic coagulation changes 
Early reports have presented hemostatic changes in IBD patients; elevation of plasma factor 
V, factor VIII, fibrinogen and thrombocytosis observed in the active IBD phase (Lam et al., 
1975; Morowitz et al., 1968). Later reports have shown an acquired plasma antithrombin 
deficiency in active IBD patients, a feature which implies a real risk of thrombosis (Knot et 
al., 1985). Subsequent studies have  shown the presence of increased markers of activate 
coagulation in both active and quiescent IBD (van Bodegraven et al., 2002; Hudson  et al., 
1992; Souto et al., 1995). In contrast other investigators did not found a significant increase 
of coagulation intermediates in IBD patients with an inactive stage (Edwards et al., 1987; 
Novacek et al., 1997; Stadnicki et al., 1997). It is assumed that the reaction with thrombin 
during the clotting activation causes consumption of plasma FXIIIa and, therefore, a fall in 
FXIII may be sign of clotting activation (Ichinose, 2001). In fact it has been found a decrease 
of FXIII subunit A, but not FXIII subunit B in both active UC (Stadnicki et al., 1991) and 
Crohn’s disease (Hudson at al., 1993). Later other investigators shown reduced level of FXIII 
active subunit A (but not carries subunit B) in active IBD patients, but generally not in 
patients with quiescent disease suggesting its consumption as result of active coagulation 
and increased turnover during active inflammation (van Bodegraven et al., 1995; Hayat et 
al., 2002).  In addition, elevated D-dimer was found almost exclusively in active IBD patients 
which provides evidence of fibrin formation and reactive fibrinolysis (Chiarantini et. al., 
1996, Hudson et al.,1992, Stadnicki et al., 1997). Natural coagulation inhibitor, protein C  
plasma level has been shown to be unchanged or decreased in IBD (Larsen et al., 2002)), 
while decreased  its cofactor, protein S plasma level was demonstrated  in most studies 
(Aadland et al., 1994; Saibeni et al., 2001). In addition, an inhibitor of tissue factor, tissue 
factor protease – inhibitor (TFPI) plasma levels have been reported to be lower in IBD (Souto 
et al., 1995). Differences between ulcerative colitis and Crohn’s diseases including disease 
location, histology, clinical course and complications although it is likely that both entities 
share similar immunoregulatory abnormalities and common pathways. The lower levels of 
coagulation intermediates or fragments  in UC  patients, as compared with Crohn’s disease, 
may be simply due to more superficial distribution of intestinal inflammation always found 
in UC. In addition patients with Cronh’s disease have higher tissue IL-1 ǃ and plasma IL-6 
levels (Mazlam & Hodgson, 1994). A role of intrinsic coagulation activation pathway, 
associated with the contact system, in IBD is unclear. FXI (an initiator of intrinsic pathway) 
is activated by thrombin (Olivier et al., 1999), or by the contact pathway initiated by 
autoactivation of FXII. Surprisingly in two large studies plasma factor XI functional level 
remained unchanged in active UC (Stadnicki et al.,  1997) and Crohn’s disease (Devani et al., 
2002). In contrast other authors observed increased active plasma level of FXII and FXI 
among other signs of thrombin generation in active UC patients suggesting both extrinsic 
and intrinsic coagulation pathways activation in active UC stage (Kume et al., 2007; 
Kyriakou  et al., 2002). However whether the plasma contact system is activated in intestinal 
circulation and if so, what is the role of HKa to maintain inflammation remains to be 
investigated. 
6.2 Systemic fibrinolytic capacity 
Disturbed fibrinolysis, which has been reported in general circulation and in colonic 
mucosa, has also been postulated to play a role in procoagulant potential in systemic 
circulation, however also in intestinal bleeding of IBD. It have been demonstrated the 
decrease of plasma t-PA with concomitant increase of its inhibitor, plasma PAI-1 indicated 
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hypofibrinolytic capacity in general circulation of IBD patients (de Jong et al., 1989). T- PA is 
mainly released by vascular endothelium, thus its plasma decrease in IBD suggests 
endotheliopathy. This phenomenon is supported by data (Gris et al., 1991) indicating 
impaired fibrinolytic response to the venous occlusion test in patients with colitis. Systemic 
endothelial cell dysfunction  has been reported in both UC and Crohn’s disease. A serum 
von Willebrand factor concentration and thrombomodulin level, the  markers of vascular 
injury have been shown to be increased in serum of IBD patients in relation with disease 
activity (Boehme MW et al., 1997; Wan der Wouwer et al., 2004). Recently discovered 
thrombin activatable fibrinolysis inhibitor (TAFI) provides link between coagulation and 
fibrinolysis (Bouma, 2004), and primarily its levels have been linked with thrombophilia in 
IBD. However TAFI plasma level in IBD is equivocal thus its significance is unclear 
(Koutroubakis et al., 2008; Saibeni et al., 2004). In addition, Italian group (Saibeni et al., 2006) 
has been demonstrated a prevalence of anti – t- PA antibodies in IBD patients which may 
reduce systemic fibrinolysis. 
6.3 Intestinal coagulation and fibrinolytic disturbances 
Nevertheless, those alterations occur in systemic circulation and, while reflecting the 
systemic inflammatory response, does not portray the actual events within the inflamed 
intestine. It has been indicated that regional vasculopathy leading to activation of 
coagulation cascade and local fibrin formation are pathogenic factors in Crohn’s disease 
(Wakefield et al., 1989, 1991). Platelets thrombi linked with fibrin, and expression of tissue 
factor were also observed in Crohn’s intestinal lesions (More et al., 1993; Wakefield et al., 
1989). Similarly mucosal capillary thrombi have been identified in UC, but similar changes 
were also found in self – limited colitis, thus their pathogenic significance in UC is less 
appreciated (Dhillon et al., 1992). However a higher platelets aggregation has been found in 
mesenteric circulation in IBD, hence circulating platelets aggregates may contribute to 
ischemic damage, and platelets aggregates have been identified histologically in rectal  
biopsies from patients with UC (Collins et al.,  1997). Latter data demonstrated that CD40L 
positive platelets adhere to mucosal endothelium in IBD, hence trigger proinflammatory 
reactions (Danese et al., 2003 a). Importantly, platelets may mediate leukocyte recruitment to 
the inflamed colon  via CD40 – CD40L (Danese et al., 2003 a),  and independently platelets 
taken from IBD patients release RANTES, a chemokine recruiting monocyte and T – 
memory cells (Fagerstam et al., 2000). In addition interaction of plaletets expressed CD40 
with CD40 expressed vascular component may increase influx of white blood cells to 
extravascular compartment. Activated protein C (APC) exert anti- inflammatory effect and 
directly maintain vascular barrier integrity. However protein C anticoagulant pathway has 
been found to be impaired in IBD, hence it may enhance thrombin generation. A reduced  
expression of endothelial protein C receptor (EPCR) in microvasculature endothelium  has 
been shown in IBD patients (Faioni et al., 2004). It is still uncertain if the intestinal vascular 
alterations in IBD is the primum movens of the disease (Wakefield et al., 1989), or the 
consequence of inflammation (Binion et al., 1998). In the inflamed mucosa of  IBD patients it 
has been  presented a decrease of t-PA and increase of  u-PA (de Bruin et al., 1988; de Jong et 
al., 1989). U-PA, in contrast to t-PA, is less fibrin dependent; thus plasmin generated due to 
u-PA may act as proinflammatory protease as well as enhance intestinal bleeding which is 
typical feature especially in UC. Interestingly u-PA is secreted as prourokinase which can be 
activated to urokinase by plasmin itself or in the cells surface by plasma kallikrein in the 
presence of  high kininogen (Ichinose et al., 1986). Urokinase binds to its receptor, uPAR, on 
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the endothelial – cell surface (Colman, 2006). Prekallikrein binds to HK, which associates 
with the same receptor hence the conversion of plasminogen to plasmin is efficient. Thus 
prekallikrein may be anti- thrombotic by virtue of its role in the fibrinolytic system.  
Although a moderate amount of FXIII has proved sufficient to secure hemostasis, its low 
level in the presence of other coagulation abnormalities may contribute to intestinal 
bleeding, but its relationship to intestinal bleeding during IBD is controversial Other 
investigations have shown enhanced local fibrinolytic activity in IBD patients which led to 
use tranaxemic acid, an antifibrinolytic agent, in the context of an increased intestinal 
bleeding tendency (Kondo et al., 1981)). This drug acts mainly preventing the interaction of 
tissue t - PA with fibrin which is required for its catalytic activity. However local fibrinolysis 
in IBD is related to u-PA, which is fibrin independent. 
7. Serine proteases act via PARs 
Four protease – activated receptors (PARs) 1-4 have been identified as mediators of cellular 
responses. It has been shown that coagulation activation may mediate inflammatory 
response, which support the concept of mutual activation of inflammatory and coagulation 
cascades in IBD. Thrombin is a key player of PARs activation as this enzyme can activate 
PAR1, 3 and 4, and in turn activates platelet and endothelial cells, whereas tissue factor can 
act due to PAR1 or 2 (Steinhoff et al., 2005). Recent study demonstrated  that active factor X 
(FXa) may induce PAR -2 activation, and in turn may mediate inflammation and fibrosis, a 
features of IBD (Borensztajn et al., 2009). Interestingly, investigation revealed that PAR1 and 
PAR2 are present on intestinal epithelium, and PAR1 has been shown to mediate intestinal 
secretion (Oikonomopoulou et al., 2006). In addition tissue kallikrein may activate directly 
B2R independently of bradykinin release. Thus in addition to thrombin and trypsin which 
can affect tissues by activating a novel family of protease activated receptors (PARs 1-4), 
tissue kallikreins represent PAR regulator, and consequently  B2R may belong to a new 
group of PARs. In animal studies  a decreased plasma protein C activation was shown in 
DDS – induced colitis in mice (Yoshida et al., 2008), and APC administered to mouse colitis 
model also provided protection against thrombosis and accompanied colonic inflammation. 
In addition via thrombin generation platelets may by activated by PARs (Biloduane & 
Hamm, 2007).  PARs activated coagulation cascade might participate in the progression of 
IBD suggesting that PARs blockade might provide a novel therapeutic target for the 
management of IBD.  
8. Platelet as inflammatory cell in IBD 
IBD patients have an increase of platelet numbers which  correlate with both UC and 
Crohn’s activity (Morowitz et al., 1968). In early 1990s it has been documented abnormal 
platelet aggregation in vitro, and activation in vivo expressed by elevation of tromboxane 
B2, tromboxane A2, and specific chemokines as platelet factor – 4 and ǃ – tromboglobulin as 
well as higher expression of P– selectin and GP53 on platelets surface in both active and 
inactive IBD phases (Collins et al., 1994, Webberley et al., 1993).  Thus platelet activation is a 
feature of IBD. During inflammation an increased endothelial exposure of adhesion 
glycoproteines may enhance binding of platelets and leukocyte. Later it has been (Danese et 
al., 2003 b) observed increased platelet expression of activation - dependent of CD40 – 
ligand (CD40L) as well as increased plasma level of soluble CD40 in both UC and Cronh’s 
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disease compared to normal controls. The increased of platelet-leukocyte aggregated (PLA) 
in systemic circulation account for platelet activation and platelet- leukocyte interaction in 
IBD patients (Irving et al., 2004). Taken together it seems that in IBD platelets show not only 
prothrombotic but also proinflammatory properties. Suppression of the adverse effect of 
thromboxane A2 can be achieved either by inhibiting its synthesis and/or antagonizing the 
receptor through which it acts. Selective antithromboxane agents have been shown to 
ameliorate experimental colitis (Vilaseca et al., 1990) however ridogrel not shown enough 
therapeutic effect (Tytgat et al., 2002). Unfortunately, ridogrel is a weaker thromboxane 
receptor antagonist than synthetase inhibitor, so that activation of the former by 
endoperoxides such as PGH-2 (accumulating after inhibition of thromboxane synthetase) 
activate thromboxane recepotors. New generation of antiplatelet compounds which 
selectively inhibit platelet activation rather than platelet aggregation merit future studies in 
IBD.  
9. Thromboembolic complications in IBD 
9.1 Risk factors for thromboembolism  
Coagulation activation in IBD is one of significant feature to enhance prothrombotic 
potential, increased risk of thromboembolism is related to extension of intestinal 
inflammation, but coagulation system abnormalities found in IBD may also be caused by 
other acquired factors. Nutritional deficiencies of vitamins B6 and B12, and folic acid in 
Cronh’s disease patients may be caused by ileitis, while sulfasalazine or methotrexate – 
induced folate deficiency may have similar effect in both Crohn’ s disease and UC. Those 
deficiencies may lead to hyperhomocysteinemia which has been found in IBD patients 
(Bjerregaard  et al., 2002). Increased level of lipoprotein (a) an independent risk factor for TE 
has been shown to account for tendency to thromboembolism in some Crohn’n disease 
patients (van Bodegraven & Meuwissen, 2001). Other ways that may predispose to 
thromboembolism in IBD include immobility, the need to undergo surgery, fluid depletion 
diarrhea – induced, and use central venous catheter for parenteral nutrition. At present no 
interaction between IBD and inherited factors of thrombophilia e.g. factor V gene (FV 
Leiden) mutation, prothrombin G20210A mutation, and methylenetetrahydrofolate 
reductase (MTHRF) gene mutation (related to hyperhomocysteinemia) were found (Guedon 
et al., 2001; Papa et al., 2001) . 
9.2 Thrombotic manifestations 
The thromboembolic complications are  common extraintestinal  manifestations in both 
Crohn’s disease and UC, appear to have a 3-4 fold increased risk of developing compared to 
control patients), and also exist in quiescent disease (Bernstein et al., 2001). Importantly 
thromboembolic complications increased risk was found to be specific for IBD because 
neither in patient with rheumatoid arthritis, nor in patients with celiac disease had an 
increased thromboembolic risk compared with their controls (Miehsler et al., 2004). Deep 
venous thrombosis and pulmonary embolism are most common thrombotic complications 
in IBD, but there were also described in unusual sites e.g. portal vein, mesenteric vein, 
retinal vein, and cerebral sinus veins. In addition arterial thromboembolic events and 
ischemic heart disease risk is increased in IBD patients, (Bernstein et al., 2008). Systemic 
thrombotic events are life – threatening since mortality related to thromboembolism in IBD 
is described in high ranges between 8% - 25 % during acute thromboembolic episodes 
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(Quera & Shanahan, 2004). As unconventional IBD treatment heparin have paid attention 
because its anti- inflammatory effect, hence heparin interferes with anti-inflammatory 
cascade by influencing cell migration into tissue and modulates a release of 
proinflammatory cytokine. Early study indicated a beneficial effect of heparin in refractory 
ulcerative colitis (Gaffyney et al., 1995). In general better therapeutic efficacy of 
unfractionated heparin (UH) than low molecular weigh heparin (LMWH) in UC is probably 
related to more beneficial immunomodulatory effect of UH (Panes et al., 2000). In fact an 
efficacy of heparin treatment in UC is still controversial and not established.  However a 
recent small open study demonstrated a reduction of inflammation using oral, slow- release 
LMWH (parnaparin) capsules in left- sided  UC patients (Pastorelli et al., 2008). It appears 
that IBD is a thrombophilic syndrome, a risk of thromboembolic events in IBD is 
multifactoral including active intestinal inflammation and malnutrition, (Quera & 
Shanahan, 2004). Prophylactic anticoagulation against thromboembolism is currently not 
fully defined, and intestinal bleeding worsening may occur. In high – risk patients e.g.  
active IBD patients confined to bad, subjects with familial thrombosis, and patients with 
myocardial infraction, or stroke before age 50 in first degree relatives  should be considered 
for using moderate dose of heparin (Zitomersky et al., 2011).  
10. Coagulation, intestinal barrier and healing 
The epithelium of the intestine creates a barrier to potentially immunogenic and noxious 
factors, including microorganisms and dietary components within the intestinal lumen. 
Healing of the intestinal surface is regulated by a complex mechanism that involves growth 
factors, cytokines, as well as intracellular matrix proteins and blood clotting factors to 
preserve homeostasis and integrity of the intestinal mucosa (Dignass & Podolsky, 2004). 
Once the intestinal epithelial barrier is damaged, luminal highly immunogenic bacterial 
antigens can enter the normally sterile submucosal layers and thus may play a role in the 
pathogenesis of IBD. The antibiotics, mainly tobramycin and metronidazole, have been 
found to be effective as adjunctive therapy not only in Crohn’s disease but also in UC 
patients (Rahimi et al. 2007). Among the regulatory peptides that are expressed within the 
intestinal mucosa, transforming growth factor-ǃ (TGF-ǃ) and epidermal growth factor 
family peptides (EGFs) play especially important role. EGFs, potent stimulators of intestinal 
epithelial cells proliferation, and may increase the concentration of bioactive TGF-ǃ, whereas 
TGF-ǃ is capable of regulating growth, differentiation, and function of immune cells 
(Stadnicki et al., 2009). Interestingly, EGF enemas have been proved to be beneficial in UC 
patients (Dieckgraefe et al. 2007).  Importantly, TGF-ǃ1 that counteracts TNF-ǂ and acts as 
negative regulator of mucosal inflammation is essential for wound healing (Blobe et al., 
2000). The role of TNF-ǂ, that occupies central position to generate the inflammatory 
cascade, has been well defined in Crohn’s disease and recently in UC (Blonski et al., 2011). 
Infliximab administered with steroids, has been found to be effective in inducing responses 
and maintaining remissions in patients with moderate and severe stage of IBD. Interestingly 
treatment with infliximab, a chimeric antibody against TNF-ǂ, has been reported not only 
induced clinical remission but also decreased thrombin generation in IBD patients (Hommes 
et al. 1997). Intestinal epithelial wound healing and tissue repair may also act trough growth 
factors independent pathway involved in cells interactions and blood coagulation factors. 
Besides fibrin, FXIIIa also cross-links actin, collagen, and fibronectin., thus it is as much 
connective tissue factor as a clotting factor. FXIII and other transglutaminases may be 
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important in the maintenance of normal intestinal integrity and intestinal repair mechanism 
(D’Argenio et al. 1995). Our and others data suggested that interaction of factor XIII subunit 
A a with its natural plasmatic substrates e. g. fibronectin and ǂ–2 plasmin inhibitor, plays a 
role in healing of UC lesions (Stadnicki et al., 1992). Consequently, factor XIIIa infusion has 
been shown to promote intestinal wound healing in both UC and Crohn’s disease patients 
(Lorenz et al., 1991; Oshitani et al., 1996). In contrast vascular endothelial growth factor 
(VEGF) increases vascular permeability to activate metaloproteinases which participate in 
degradation of extracellular matrix, hence may have detrimental effect on intestinal barrier 
(Ferrara, 2004). 
11. Kinins and angiogenesis in IBD 
Recently it has been provided the direct evidences that angiogenesis has a role in the  
pathogenesis of both UC and Crohn’s disease showing a higher density of microvessels 
within intestinal mucosa and sub-mucosa and increased expression of ǂvǃ3 - integrin in 
endothelium with simultaneous increase of intestinal VEGF expression (Danese et al., 2006) . 
Most recent data demonstrated the increase of genes expression as well as protein levels for 
VEGF and its Flt-1 receptor in active inflammatory colonic tissue and increased VEGF levels 
in serum and plasma in active UC patients (Frysz – Naglak et al., 2011). TGF-ǃ1 may directly 
stimulate angiogenesis in vivo; the stimulation can be blocked by TGF-ǃ1 antibodies 
(Pepper, 1997). The influence of kinins in angiogenesis has recently been appreciated. Kinin 
promotes angiogenesis by upregulation of basic fibroblast growth factor through bradykinin 
- B1 receptor and by stimulation of VEGF formation by bradykinin both B1 and B2 receptors 
(Colman, 2006 b), and kinins may act synergistically with TGF-ǃ1. Monoclonal antibody 
C11C1 which prevents binding HK to endothelial cells also limits its conversion to 
bradykinin thus downregulating angiogenesis (Colman et al. 2000). Thus, it is possible that 
kinins as proangiogenic may promote angiogenesis in IBD although the interaction between 
kinins and growth factors is highly complex, and requires future investigation. In contrast 
HKa or its domain 5 inhibit endothelial cells migration and proliferation needed for 
angiogenesis (Colman et al, 2003).  
12. Conclusions  
IBD appear to be immunologically mediated by activation of immune system cells and 
plasma proteolytic cascades. Products of activated cells such as cytokines, eicosanoids, 
lysosomal enzymes as well as kallikrein – kinin and coagulation system are reported to be 
increased in intestinal lesions and in the systemic circulation of IBD. The activation of 
coagulation has been recognized as important component of the inflammatory response in 
both Crohn’s disease and UC, and also is significant in progression and possibly 
pathogenesis of these entities. A significance of coagulation in IBD was underestimated, 
now it appears that IBD is a thrombophilic syndrome in both active and  quiescent phases. 
A risk of thromboembolic events in IBD is multifactoral including coagulation activation. 
Prophylactic anticoagulation against thromboembolic complications is currently not fully 
defined, however high – risk patients should be considered for using moderate dose of 
heparin. Kinins exert their biological effect  by activating constitutive bradykinin  receptor -2 
(BR2), which are rapidly desensitized, and inducible by inflammatory cytokines bradykinin 
receptor -1 (BR1), resistant to densensitization. Intestinal tissue kallikrein (ITK) may 
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hydrolyze growth factors and peptides whereas kinins increase capillary permeability, 
evoke pain, stimulate synthesis of nitric oxide and cytokines, and promote adhesion 
molecule – neutrophil  cascade. Thus activation of intestinal kallikrein – kinin system may 
have relevance to idiopathic inflammatory bowel disease (IBD). These results promise to 
yield new insight in the pathogenesis of IBD. Currently it seems that upregulation of 
bradykinin B1 recepror (B1R) in human and animal intestinal inflammation provides a 
structural basis for the kinins function, and  selective B1R antagonist may have potential in 
therapeutic trial of IBD patients. 
13. References  
Aadland E, Odegaard OR, Roseth A, Try K. (1994). Free protein S deficiency in patients with 
Cronh’s disease. Scand J Gastroenterol, 29,  333- 5. 
Andoh A, Tsujikawa T, Hata K, et al.(2005). Elevated circulating platelet – derived 
microplates in patients with active inflammatory bowel disease. Am J Gastroenterl,  
100,  2042 – 8. 
Arai Y, Takanashi H, Kitagawa H, et al. (1999). Effect of Icatibant, a bradykinin receptor -2 
antagonist, on the development of experimental ulcerative colitis in mice. Dig Dis 
Sci, 44, 845 – 851. 
Bachvarov DR, Houle S, Bachvarova M, et al.(2001).  Bradykinin B(2) receptor endocytosis, 
recycling, and down-regulation assessed using green fluorescent protein 
conjugates.  J Pharmacol Exp Ther, 297, 19-26. 
Bachvarov DR, Landry M, Houle S, et al. (1998). Altered frequency of a promoter 
polymorphic allele of the kinin B1 receptor gene in inflammatory bowel disease. 
Gastroenterology 115, 1045 - 1058. 
Baumgart DC, Carding SR. (2007). Gastroenterology 1. Inflammatory bowel disease: cause 
and immunobiology. Lancet, 369, 1627- 40. 
Bernstein CN, Blanchard JF, Houston DS, Wajda A.(2001). The incidence of deep venous 
thrombosis and pulmonary embolism among patients with inflammatory bowel 
disease: a population-based cohort study. Thromb Haemost, 85, 430– 4. 
Bernstein CN, Wajda A, Blanchard JF. (2008). The incidence of arterial thromboembolic 
disease in inflammatory bowel disease: a population based study. Clin Gastroenterol 
Hepatol, 6, 41-5. 
Bhoola KD, Figueroa CD, Worthy K. (1992). Bioregulation of kinins: Kallikreins, kininogens, 
and Kininases. Pharmacol Rev, 44, 1- 80. 
Biloduane LM, Hamm HE.(2007). Regulation of protease- activated receptor PAR1 and 
PAR4 signaling in human platelets by compartmentalized cyclic nucleotide action. J 
Pharm Exp Ther, 322, 778 – 88. 
Binion DG, West GA, Volk EE, et al. (1998). Acquired increase in leucocyte binding by 
intestinal microvascular endothelium in inflammatory bowel disease. Lancet, 352, 
1742 – 6. 
Bjerregaard LT, Nederby NJ, Fredholm L, Brandslund I, Munkholm P, Hey H.(2002). 
Hyperhomocysteinaemia,  coagulation pathway activation and thrombophilia in 
patients with  inflammatory bowel disease. Scand J Gastroenterol, 37, 62-7. 
Blobe GC, Schiemann WP, Lodish HF. (2000). Role of transforming growth factor beta in 
human disease.N Engl J Med, 342, 1350-1358. 
www.intechopen.com
 
Kallikrein – Kinin System and Coagulation System in Inflammatory Bowel Diseases 
 
189 
Blonski W, Stadnicki A, Lichtenstein G, Burke A. Infliximab use in ulcerative colitis. In: 
Ulcerative Colitis. The complete quid to medical management. Editors: GR 
Lichtenstein and EJ Scherl. Slack Inc. 2011. 
Boehme MW, Autschbach F, Zuna I, et al. (1997). Elevated serum levels and reduced 
immunohistochemical expression  of thrombomodulin in active ulcerative colitis. 
Gastroenterology, 113, 107 – 17. 
Borensztajn K, Peppelenbosch MP, Spek CA. (2009). Coagulation and factor Xa signaling: 
the link between coagulation and inflammatory bowel disease? Trends Pharmacol 
Sci,  30, 8-16. 
Bouma BN, Mosnier LO. (2004). Thrombin activatable fibrinolysis inhibitor (TAFI) at the 
interface between coagulation and fibrinolysis. Pathophysiol Haemost Thromb,  33, 
375- 81. 
Calixto JB, Medeiros L, Fernandes ES, et al. (2004). Kinin B1 receptors: key G – protein 
coupled receptors and their role in inflammatory and painful processes. Br J 
Pharmacol, 143, 803 – 818. 
Campbell D.(2001). The kallikrein – kinin system in humans. Clin Exp Pharmacol Physiol, 28, 
1060-1065. 
Chao J, Chao L.(2004).  Kallikrein – kiinin in stroke, cardiovascular and renal disease. Exp 
Physiol, 90, 291 – 298. 
Chao J, Schmaier AH, Chen LM, et al.(1996). Kallistatin, a novel human tissue kallikrein 
inhibitor: Levels in body fluids, blood cells, and tissues in health and disease.  J Lab 
Clin Med, 127, 612-620. 
Chen LM, Richards GP, Chao L, et al.(1995).  Molecular cloning, purification and in situ 
localization of human colon kallikrein.  Biochem J, 307, 481-486. 
Chiarantini F, Valanzano R, Liotta AA, et al.(1996). Hemostatc abnormalities in 
inflammatory bowel disease. Thromb Res, 82, 137-  46. 
Clements J, Mukhtar A, Ehrlich A, et al.(1992). A re-evaluation of the tissue-specific pattern 
of expression of the rat kallikrein gene family. Agents Actions, 38, 34-41.  
Collins CE, Cahill MR, Newland AC, Rampton DS.(1994).  Platelets circulate in an activated 
state in inflammatory bowel disease. Gastroenterology, 106, 840 – 45. 
Collins CE, Rampton DS, Rogers J, et al. (1997). Platelet aggregation and neutrophil 
sequestration in the mesenteric circulation in inflammatory bowel disease. Eur J 
Gastroenterol Hepatol, 9, 1213-17. 
Colman RW. (2006 a). Are hemostasis and thrombosis two sides of the same coin? JEM, 203,  
493- 5. 
Colman RW. (2006 b). Regulation of angiogenesis by the kallikrein-kinin system. Cur 
Pharmaceut Des, 12, 599-607. 
Colman RW, Jameson BA, Lin Y, et al.(2000). Domain 5 of high molecular weight kininogen 
(kininostatin) down-regulates endothelial cell proliferation and migration and 
inhibits angiogenesis. Blood, 95, 543-550. 
Colman RW, Pixley RA, Sainz IM,  et al.(2003).  Inhibition of angiogenesis by antibody 
blocking the action of proangiogenic high-molecular-weight kininogen. Thromb 
Haemostas, 1, 164- 170.   
Colman RW. (2006 c). Contact activation (kallikrein – kinin) pathway: multiple physiologic 
and pathophysiologic activities. In: Colman RW, Marder VJ, Cloves AW, et al. ed. 
www.intechopen.com
 
Ulcerative Colitis – Epidemiology, Pathogenesis and Complications 
 
190 
Hemostasis and  Thrombosis. Basic Principles and Clinical Practice.5th ed. Philadelphia: 
Lippincott Wiliams&Wilkins, pp.103 – 121. 
Cuthbert AW. (2001). Kinins and epithelial ion transport in the alimentary tract. Biol Chem, 
382, 57-60. 
D’Argenio G, Biancone L, Cosenza V, et al.(1995).  Transglutaminases in Cronh’s disease. 
Gut, 37, 690 – 5. 
Danese S, de La Motte C, Sturm A, et al. (2003 a). Platelets trigger a CD40 – dependent 
inflammatory response in the microvasculature of  inflammatory bowel disease 
patients. Gastroenterology, 124, 1249 – 64. 
Danese S, Katz JA, Saibeni S, et al. (2003 b). Activated platelets are the source of elevated 
levels of soluble  CD40 ligand in the circulation of inflammatory bowel disease 
patients. Gut, 52, 1435 – 41.  
Danese S, Papa A, Saibeni S, Repici A, Malesci A, Vecchi M. (2007).  Inflammation and 
coagulation in inflammatory bowel disease: the clot thickens. Am J Gastroenterol, 
102, 174- 86. 
Danese S, Sans M, de LaMotte C, et al. (2006). Angiogenesis as a novel component of 
inflammatory bowel disease pathogenesis. Gastroenterology, 130: 2060-2073. 
de Bruin PA, Crama-Bohbout G, Verspaget HW, et al. (1988). Plasminogen activators in the 
intestine of patients with inflammatory bowel disease. Thromb Haemost, 60, 262 6. 
de Jong E, Porte RJ, Knot EA, Verheijen JH, Dees J.(1989). Disturbed fibrinolysis in patients 
with inflammatory bowel disease. A study of blood plasma, colon mucosa, and 
faeces. Gut, 30, 188 – 94. 
DeLa Cadena R, Majluf - Cruz A, Stadnicki A, et al.(1998). Recombinant tumor necrosis 
factor receptor (TNFR: Fc) alters endotoxin – induced activation of the kinin, 
fibrinolytic, and coagulation system in normal human subjects. Thromb Haemostas, 
80, 114 – 118. 
Devani M, Cugno M, Vecchi M, et al.(2002).  Kallikrein - kinin system activation in Crohn's 
disease: Differences in intestinal and systemic markers. Amer J Gastroenterol, 97: 
2026 - 2032. 
Devani M, Vecchi M, Ferrero S, et al. (2005). Kallikrein – kinin system in inflammatory 
bowel disease : intestinal involvement and correlation with the degree of tissue 
inflammation. Dig Liver Dis, 37, 665 – 673. 
Dhillon AP, Anthony A, Sim R,  et al. (1992). Mucosal capillary thrombi in rectal biopsies. 
Histopathology, 21: 127 – 33.  
Dieckgraefe BK, Korzenik JR, Anant S.(2006). Growth factors as treatment options for 
intestinal inflammation. Ann N Y Acad Sci, 1072, 300-306. 
Dignass AU, Podolsky DK.(2004). Epithelial restitution and intestinal repair. In: Sartor RB, 
Sandborn WJ, editors. Kirsner’s inflammatory bowel diseases. Philadelphia: 
Saunders, pp. 18-29. 
Drey A. (1997). Kinins and their receptors in hyperalgesia. Br J Pharmacol, 75, 704-712. 
Edwards RL, Levine JB, Green R, et al.(1987). Activation of blood coagulation in Crohn’s 
disease. Increased plasma fibrinopeptide A levels and enhanced generation of 
monocyte tissue factor activity. Gastroenterology, 92: 329 – 37.  
Fagerstam JP, Whiss PA, Strom M, Andersson RG.(2000). Expression of platelet P – selectin 
and detection of soluble P-selectin, NPY and RANTES in patients with 
inflammatory bowel disease. Inflamm Res, 49, 466 – 72. 
www.intechopen.com
 
Kallikrein – Kinin System and Coagulation System in Inflammatory Bowel Diseases 
 
191 
Faioni FM, Ferrero S, Fontana G, et al.(2004). Expression of endothelial protein C receptor 
and thromomodulin in the intestinal tissue of patients with inflammatory bowel 
disease. Crit Care Med, 32 (suppl 5): S266 – 70.  
Fasth S, Hulten L.(1973). The effect of bradykinin on intestinal motility and blood flow. Acta 
Chir Scand, 139, 699 – 705.  
Ferrara N.(2004). Vascular endothelial growth factor: basic science and clinical progress. 
Endocr Rev, 25, 581-611. 
Figueroa CD, MacIver AG, Bhoola KD.(1998). Identification of tissue kallikrein in human 
polymorphonuclear leucocytes. Br J Haematol, 72, 321-328. 
Frysz-Naglak D,  Fryc B, Klimacka-Nawrot E, Mazurek U,   Suchecka W, Kajor M,  Kurek J  
Stadnicki A.(2011). Expression, localization and  systemic concentration of vascular 
endothelial growth factor (VEGF) and its receptors in patients with ulcerative 
colitis. International Immunopharmacol, 11, 220-225.  
Gaffyney PR, Doyle CT, Gaffyney A, et al.(1995). Paradoxical response to heparin in 10 
patients with ulcerative colitis. Am J Gastroenterol, 90, 220 – 3. 
Gaginella TS, Kachur J F. (1989). Kinins as mediators of intestinal secretion. Am J Physiol, 
256:G1-15 
Gardiner KR, Halliday MI, Barclay GR, et al. (1995).  Significance of systemic endotoxemia 
in inflammatory bowel disease. Gut, 36, 897-901. 
Gregory SA, Edgington TS.(1985). Tissue factor induction in human monocytes: Two 
distinct mechanisms displayed by different alloantigen responsive T cell clones. J 
Clin Invest, 76, 2440-2445. 
Gris JC, Schved JF, Raffanel C, Dubois A, Ribard D, Balmes JL.(1991). Impaired fibrinolytic 
response to the venous occlusion test in patients with cryptogenic 
colitis.Gastroenterol Clin Biol, 15, 933-8. 
Guedon C, Le Camp Duhes V, Lalaude O, Menard JF, Lerebous E, Borg JY.(2001). 
Prothrombotic inherited abnormalities other than factor V Leiden mutation do not 
play a role in venous thrombosis in inflammatory bowel disease. Am J 
Gastroenterol, 96, 1448- 54. 
Hara DB, Fernandes ES, Campos MM, at al.(2007). Pharmacological and biochemical 
characterization of B2 receptors in the mouse colon :Influence of the TNBS-induced 
colitis. Regul Pept, 141, 25-34. 
Hara DB, Leite DFP, Fernandes ES, et al.(2008). The relevance of kinin B1 receptor 
upregulation in a mouse model of colitis. Br J Pharmacol, 154, 1276 -1286. 
Hayat M, Ariëns RA, Moayyedi P, Grant PJ, O' Mahony S.(2002). Coagulation factor XIII and 
markers of thrombin generation and fibrinolysis in patients with inflammatory 
bowel disease. Eur J Gastroenterol Hepatol, 14: 249-56. 
He SH.(2004). Key role of mast cells and their major secretory products in inflammatory 
bowel disease. World J Gastroenterol, 10,  309-18.  
Hoffman M, Monroe DM.(2007).  Coagulation: A modern view of hemostasis. Hematol Oncol 
Clin North Am, 21: 1-11.  
Hommes DW, van Dullemen HM, Levi M, et al. (1997). Beneficial effect of treatment with a 
monoclonal anti – tumor necrosis factor- ǂ antibody on markers of coagulation and 
fibrinolysis  in patients with Cronh’s disease. Haemostasis, 27: 269 – 77. 
Hudson M, Hutton RA, Wakefield AJ, Sawyerr AM, Pounder RE.(1992).  Evidence for 
activation of coagulation in Crohn’s disease. Blood Coagul Fibrinolysis, 3, 773 –8.  
www.intechopen.com
 
Ulcerative Colitis – Epidemiology, Pathogenesis and Complications 
 
192 
Hudson M, Wakefield AJ, Hutton RA, et al. (1993). Factor XIIIA subunit and Crohn’s 
disease. Gut, 34, 75- 9. 
Ichinose A, Fujikawa K, Suyama T.(1986). The activation of prourokinase by plasma 
kallikrein and its inactivation by thrombin. J Biol Chem, 261, 3486-3489. 
Ichinose A.(2001).  Physiopathology and regulation of factor XIII. Thromb Haemost, 86, 57 – 
65. 
Irving PM, Macey MG, Shah U, et al.(2004).  Formation of platelet – leukocyte aggregates in 
inflammatory bowel disease. Inflamm Bowel Dis, 10, 361 – 72.  
Isordia Salas I, Pixley RA, Parekh H, Li F, Kanapuli SP, Stadnicki A, Lin Y, Sartor RB, 
Colman RW. (2003). A single point mutation of serine S11 is responsible for the 
increased rate of cleavage of high molecular weight kininogen in Lewis rat which is 
genetically susceptible to inflammatory stimuli. Blood, 102, 2835 – 2842.  
Khan MM, Bratford HN, Isordia – Salas I, et al .(2006).  High molecular kininogen fragments 
stimulate the secretion of cytokines and chemokines through uPAR, Mac-1, and 
gC1qR in monocytes. Arterioscler Thromb Vasc Biol, 26, 2260-2266. 
Knot EA, ten Cate JW, Bruin T, Iburg AH, Tytgat GN.(1985).  Antithrombin III metabolism 
in two colitis patients wit acquired antithrombin III deficiency. Gastroenterology, 89: 
421- 5. 
Kondo M, Hotta T, Takemura S, Yoshikawa T, Fukumoto K.(1981). Treatment of ulcerative 
colitis by the direct administration o fan antifibrinolytic agent as an enema. 
Hepatogastroenterology, 28, 270 – 3.  
Koutroubakis IE, Sfiridaki A, Tsiolakidou G, Coucoutsi C, Theodoropoulou A, Kouroumalis 
EA.(2008).  Plasma thrombin-activatable fibrinolysis inhibitor and plasminogen 
activator inhibitor-1 levels in inflammatory bowel disease. Eur J Gastroenterol 
Hepatol, 20, 912- 6. 
Kume K, Yamasaki M, Tashiro M, Yoshikawa I, Otsuki M.(2007). Activation of coagulation 
and fibrinolysis secondary to bowel inflammation in patients with ulcerative colitis. 
Internal Medicine,  46, 1323- 9. 
Kyriakou DS, Aleksandrakis MG, Passam FH et al. (2002).Acquired inhibitors of coagulation 
factors in patients with gastrointestinal diseases. Eur J Gastroenterol Hepatol, 14, 
1383- 7. 
Lam A, Borda IT, Inwood MJ, Thomson S. (1975). Coagulation studies in ulcerative colitis 
and Chron’s disease. Gastroenterology 68: 245 – 51. 
Larsen TB, Nielsen JN, Fredholm L, et al. (2002).  Platelets and anticoagulant capacity in 
patients with inflammatory bowel disease. Pathophysiol Haemost Thromb, 32, 92-6.  
Lewis GP. (1964). Plasma kinins and inflammation. Metabolism, 13, 1256 – 1263. 
Lichtenstein GR.(2000).  Goblet cells make more than just mucus. Gastroenterology, 118, 1272 
– 1274. 
Lorenz R, Heinmullr M, Classen M, Tornieporth N, Gain T. (1991).  Substitution of factor 
XIII: a therapeutic approach to ulcerative colitis. Haemostasis, 21, 5- 9. 
Manning DC, Snyder SH, Kachur JF, et al. (1982). Bradykinin receptor-mediated chloride 
secretion in intestinal function. Nature, 299, 256-259. 
Marceau F, Regoli D.(2008). Therapeutic options in inflammatory bowel disease: 
experimental evidence of a beneficial effect of kinin B1 receptor blockade. Br J 
Pharmacol, 154, 1163-1165. 
www.intechopen.com
 
Kallikrein – Kinin System and Coagulation System in Inflammatory Bowel Diseases 
 
193 
Marceau F, Tremblay B (1986). Mitogenic effect of bradykinin and of des- Arg9- bradykinin 
on cultured fibroblast. Life Sci, 39, 2351 – 2358.  
Mazlam MZ, Hodgson HJ.(1994). Interaction between interleukin – 6, interleukin-1 beta, 
plasma C-reactive protein values, and in virtro C-reactive protein generation in 
patients with inflammatory bowel disease. Gut, 35, 77-  86.  
McLean PG, Ahluwalia A, Perretti M. (2000). Association between kinin B1 receptor 
expression and leukocyte trafficking across mouse mesenteric postcapillary 
venules. J Exp Med, 192, 367 – 380. 
Meucci G, Pareti F, Vecchi M, et al. (1999). Serum von Willebrant factor  levels in patients 
with inflammatory bowel disease are related to systemic inflammation. Scand J 
Gastroenterol, 34, 287 – 90. 
Miehsler W, Reinisch W, Valic E, et al.(2004). Is inflammatory bowel disease an independent 
and disease specific risk factor for thromboembolism? Gut, 53, 542– 8.  
Min B, Paul WE. (2008). Basophils in the spotlight at last. Nature Immunol,  9, 223-225. 
More L, Sim R, Hudson M, et al. (1993). Immunohistochemical study of tissue factor 
expression in normal intestine and idiopathic inflammatory bowel disease. J Clin 
Pathol, 46: 703-8. 
Moreau ME, Garbacki N, MolinaroG, et al.(2050). The kallikrein – kinin system: current and 
future pharmacological targets. J Pharmacol Sci,  99, 6-38. 
Morowitz DA, Allen LW, Kirsner JB.(1968). Thrombocytosis in chronic inflammatory bowel 
disease. Ann Intern Med, 68, 1013 – 21.  
Ni A, Chao L, Chao J. (1998). Trancriptional factor nuclear factor-kB regulates the inducible 
expression of the human receptor gene in inflammation. J Biol Chem, 273, 2784-2791. 
Novacek G, Kapiotis S, Moser G, Speiser W, Gangl A, Vogelsang H. (1997). No evidence of 
activated blood coagulation in Crohn’s disease. Eur J Gastroenterol Hepatol, 9, 963 – 
7. 
Oikonomopoulou K, Hansen KK, Saifeddine M, et al. (2006).  Proteinase – activated 
receptors, targets for kallikrein signalling. J Biol Chem, 281, 32095 – 32112. 
Okamoto H, Greenbaum LM. (1993). Isolation and stricture of T-kinin. Biochem Biophys Res, 
112, 701 – 708 
Oliver JA, Monroe DM, Roberts HR, Hoffman M.(1999). Thrombin activates factor XI on 
activated platelets in the absence of factor XII. Arterioscler Thromb Vasc Biol, 19, 170 
– 7. 
Oshitani N, Nakamura S, Matsumoto T, Kobyashi K, Kitano A. (1996).  Treatment of Crohn’s 
disease fistulas with coagulation factor XIII. Lancet, 347, 119- 20. 
Panes J, Esteve M, Cabre E et al. (2000). Comparison of heparin and steroid in the treatment 
of moderate and severe ulcerative colitis. Gastroenterology, 119, 903-8.  
Papa A, De Stefano V, Gasbarrini A, et al. (2000). Prelevalence of factor V Leiden and the 
G20210A prothrombin –gene mutation in inflammatory bowel disease Blood Coagul 
Fibrinolysis, 11, 499-503. 
Pastorelli L, Saibeni S, Spina L, et al. (2008).Oral- colonic release low – molecular weight 
heparin: an initial open study of  Parnaparin- MMX for the treatment of mild – to  
moderate left – sided ulcerative colitis. Aliment Pharmacol Ther, 28: 581- 88.  
Peppers MS. (1997). Transforming grow factor-beta: vasculogenesis, angiogenesis, and 
vessel wall integrity. Cytokine Growth Factor Rev, 8, 21-43. 
www.intechopen.com
 
Ulcerative Colitis – Epidemiology, Pathogenesis and Complications 
 
194 
Pixley RA, Zellis S, Bankes P, et al. (1995).  Prognostic value of assessing  contact system 
activation and factor V in systemic inflammatory  response syndrome. Crit Care 
Med, 23, 41- 51. 
Quera R, Shanahan F. (2004). Thromboembolism – an important manifestation of 
inflammatory bowel disease. Am J Gastroenterol, 99:1971-3. 
Rahimi R, Nikfar S, Rezaie A, Abdollahi M. (2007).  A meta-analysis of antibiotic therapy for 
active ulcerative colitis. Dig Dis Sci, 52:2920-2925.  
Rao AK, Schapira M, Clements ML, et al. (1988). A prospective study of Rocky Mountains 
spotted fever. N Engl J Med. 318, 1021 – 1028. 
Rupniak NM, Boyce S, Webb JK, et al. (1997). Effect of the bradykinin B1receptor antagonist  
des – Arg9 (Leu 8) bradykinin and genetic disruption of the B2 receptor on 
nociception  in rats and mice. Pain, 71, 89-97 
Sabourin T, Bastien L, Bachvarov DR, et al. (2002).  Agonist-induced translocation of the 
kinin B1 receptor to caveolae-related rafts.  Mol Pharmacol, 61: 473-476. 
Saibeni S, Bottasso B, Spina L, et al. (2004). Assessment of thrombin-activatable fibrilolysis 
inhibitor (TAFI) plasma levels in inflammatory bowel diseases. Am J Gastroenterol, 
99, 1966-70. 
Saibeni S, Ciscato C, Vecchi M, at al. (2006). Antibodies to tissue – type plasminogen 
activator (t-PA) in patients with inflammatory bowel disease: high prevalence, 
interaction with functional domains of t-PA and possible implications in 
thrombosis. J Thromb Haemost, 4, 1510-6. 
Saibeni S, Vecchi M, Valsecchi C, et al. (2001). Reduced free protein S levels in patients with 
inflammatory bowel disease. Prelevalece, clinical relevance, and role of anti – 
protein S antibodies. Dig Dis Sci, 46, 637 – 43.  
Sartor RB, DeLa Cadena RA, Green KD, Stadnicki A, Davis S, Schwab JH, Adam A, 
Raymond P, Colman  RW. (1996). Selective kallikrein-kinin system activation in 
inbred rats differentially susceptible to granulomatous enterocolitis.  
Gastroenterology, 110, 1467-1481. 
Sartor RB.(2006). Mechanism of disease: pathogenesis of Crohn’s disease and ulcerative 
colitis. Nature Clin Pract Gastroenterol Hepatol, 3, 390- 407. 
Schachter M, Longridge DJ, Wheleer GD, et al. (1986). Immunohistochemical and enzyme 
histochemical localization of killikrein – like enzymes in colon, intestine, and 
stomach of rat and cat. J Histochem Cytochem, 34, 926-934. 
Schapira M, Despland E, Scott CF, et al. (1982). Purified human plasma kallikrein aggregates 
human blood neutrophils. J Clin Invest, 69, 1199-1202. 
Souto JC, Martinez E, Roca M, et al.  (1995). Prothrombotic state and signs of endothelial 
lesion in plasma of patients with inflammatory bowel disease. Dig Dis Sci, 40, 1883- 
9.  
Souza DG, Lomez ES, Pinho V, et al. (2004). Role of bradykinin B(2) and B(1) receptors in the 
local, remote, and systemic inflammatory responses that follow intestinal ischemia 
and reperfusion injury.  J Immunol, 172, 2542-2548. 
Stadnicki A, Chao J, Stadnicka I, et al.(1998 a).  Localization and secretion of tissue kallikrein 
in peptidoglycan-induced enterocolitis in Lewis rats.  Am J Physiol, 275, G854-G861. 
Stadnicki A, DeLa Cadena R, Sartor RB, et al (1996). A selective plasma kallikrein inhibitor 
attenuates acute enterocolitis in the Lewis rats. Dig Dis Sci, 41, 912 – 920. 
www.intechopen.com
 
Kallikrein – Kinin System and Coagulation System in Inflammatory Bowel Diseases 
 
195 
Stadnicki A, Gonciarz M, Niewiarowski TJ, et al.(1997). Activation of plasma contact and 
coagulation systems and neutrophils in the active phase of ulcerative colitis. Dig 
Dis Sci, 42,  2356-2366. 
Stadnicki A, Kloczko J, Nowak A, Sierka E, Sliwinski Z.(1991). Factor XIII subunits in 
relation to some other hemostatic parameters in ulcerative colitis. Am J 
Gastroenterol, 86, 690 – 3.  
Stadnicki A, Kłoczko J, Nowak A, Sierka E.(1992) Alterations of haemostatic parameters in 
special references to factor XIII and fibronectin in patients with ulcerative colitis. 
Eur J Gastroenterol Hepatol, 4, 743- 6. 
Stadnicki A, Machnik G, Klimacka-Nawrot E, et al. (2009).  Expression, immunolocalization 
and systemic concentration of transforming grow factor - ǃ1 and its receptors in 
human ulcerative colitis. Int Immunopharmacol, 9, 761-766. 
Stadnicki A, Mazurek U, Gonciarz M, et al.(2003) Immunolocalization and expression of 
kallistatin and tissue kallikrein in human inflammatory bowel disease.  Dig Dis Sci, 
48, 615-623. 
Stadnicki A, Pastucha E, Nowaczyk G, et al.(2005).  Immunolocalization and expression of 
kinin B1 and B2 receptors in human inflammatory bowel disease. Am J Physiol,  289, 
G361-G366.  
Stadnicki A, Sartor RB, Fengling Li, et al (1999). Bradykinin B-2 recepror antagonist 
attenuates arthritis, but not gut inflammation in Lewis rats. Gut, Suppl. 5,  Abs. 
1094. 
Stadnicki A, Sartor RB, Janardham R, at al. (1998 b). Specific inhibition of plasma kallikrein 
modulates chronic granulomatous intestinal and systemic inflammation in 
genetically susceptible rats. FASEB J, 12, 325-333. 
Stadnicki A, Sartor RB, Janardham R, et al.(1998 c).  Kallikrein-kininogen system activation 
and bradykinin (B2) receptors in indomethacin-induced enterocolitis in genetically 
susceptible Lewis rats. Gut, 43, 365-374. 
Stanley CM, Philips TE.(1994). Bradykinin modulates mucin secretion  but not synthesis 
from an intestinal goblet cell line. Agents Actions, 42, 141-145.  
Steinhoff M, Buddenkotte J, Shpacovitch V, et al. (2005). Proteinase activated receptors: 
transducers of proteinase mediated signaling in inflammation and immune 
response. Endoc Rev, 26, 1- 43.  
Techesche H, Kohnerty V, Fedowitz J, et al. (1983) Tissue kallikrein effectively activates 
latent matrix degrading matalloenzymes. Adv Exp Med Biol,  247A, 545-548. 
Tiffany C, Burch RM.(1989). Bradykinin stimulates tumor necrosis factor and interleukin-1 
release from macrophages. FEBS Lett, 247, 189-192. 
Tytgat GN, Van Nueten L, Ven de Velde I, et al. (2002). Efficacy and safety of oral ridogrel in 
the treatment of ulcerative colitis: two multicenter randomized , double blind 
studies. Aliment Pharmacol Ther, 16, 87 – 99. 
Ulbrich H, Eriksson EE, Lindbom L.(2003). Leucocyte and endothelial cell adhesion 
molecules as targets for therapeutic interventions in inflammatory disease. Trends 
Pharmacol Sci, 24, 640-647. 
van Bodegraven AA, Meuwissen SG. (2001) Lipoprotein (a), thrombophilia and 
inflammatory bowel disease. Eur J Gastroenterol Hepatol, 13, 1407- 9. 
www.intechopen.com
 
Ulcerative Colitis – Epidemiology, Pathogenesis and Complications 
 
196 
van Bodegraven AA, Schoorl M, Linskens RK, Bartels PC, Tuynman HA. (2002). Persistent 
activation of coagulation and fibrinolysis after treatment of active ulcerative colitis. 
Eur J Gastroenterol  Hepatol, 14, 413- 8. 
van Bodegraven AA, Tuynman HA, Schoorl M, Kruishoop AM, Bartels PC.(1995). 
Fibrinolytic split product, fibrinolysis and factor XIII activity in inflammatory 
bowel disease. Scand J Gastroenterol, 30, 580-5. 
Vilaseca J, Salas A, Guarner F,Rodriguez R, Malagelada JR. (1990). Participation of 
thromboxane and other eicosanoid synthesis in the course of experimental 
inflammatory colitis. Gastroenterology, 98, 269-277. 
Wachtfogel YT, Kucich U, James HL, et al. (1983). Human plasma kallikrein releases 
neutrophil elastase during blood coagulation.  J Clin Invest, 72, 1672-1677. 
Wakefield A, Sabkey EA, Dhillon A, et al. (1991). Granulomatous vasculitis in Crohn’s 
disease. Gastroenterology, 100, 1279- 87. 
Wakefield A, Sawyerr A, Dhillon A, et al. (1989). Pathogenesis of Crohn’s disease: multifocal 
gastrointestinal infarction. Lancet, 2, 1057 -62. 
Wan der Wouwer D, Collen D, Conway EM.(2004). Thrombomodulin- protein C – EPCR 
system: integrated to regulate coagulation and inflammation. Arterioscler Thromb 
Vasc Biol, 24: 1374 – 83.  
Webberley MJ, Hart MT, Melikian V, et al. (1993). Thromboembolism in inflammatory bowel 
disease: role of platelets. Gut, 34, 247 – 51. 
Werle E. (1960). Kallikrein, kallidin and related substances. In: Schachter M ed. Polypeptides 
which affect smooth muscles and blood vessels. Pergamon  Press, Oxford, England.  
Wolf WC, Harley RA, Sluce D,et al. (1998). Cellular localization of kallistatin and tissue 
kallikrein in human pancreas and salivary glands.  Histochem Cell Biol, 110, 477-84. 
Xiong W, Tang CQ, ZhouGX et al. (1992).  In vivo catabolism of human kallikrein – binding 
protein and its complex with tissue kallikrein. J Lab Clin Med, 119, 514-521. 
Yoshida H, Russell J, Stokes KY, et al. (2008).  Role of the protein C pathway in the 
extraintestinal thrombosis associated with murine colitis. Gastroenterology, 135: 
882-8. 
Zeitlin IJ, Smith AN.(1973). Mobilization of tissue kallikrein in inflammatory disease of the 
colon. Gut, 14, 133-138. 
Zipser R, Patterson J, Kao H, et al. (1985). Hypersentive prostaglandin and thromboxane 
response to hormones in rabbit colitis. Am J Physiol,  249: G457-G463. 
Zitomersky NL, Verhave M, Trenor CC. (2011). Thrombosis and inflammatory bowel 
disease: a call for improved awareness and prevention. Inflamm Bowel Dis, 17, 458- 
70. 
 
www.intechopen.com
Ulcerative Colitis - Epidemiology, Pathogenesis and Complications
Edited by Dr Mortimer O'Connor
ISBN 978-953-307-880-9
Hard cover, 280 pages
Publisher InTech
Published online 14, December, 2011
Published in print edition December, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
This book is intended to act as an up-to-date reference point and knowledge developer for all readers
interested in the area of gastroenterology and in particular, Ulcerative Colitis. All authors of the chapters are
experts in their fields of publication, and deserve individual credit and praise for their contributions to the world
of Ulcerative Colitis. We hope that you will find this publication informative, stimulating, and a reference point
for the area of Ulcerative colitis as we move forward in our understanding of the field of medicine.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Antoni Stadnicki (2011). Kallikrein – Kinin System and Coagulation System in Inflammatory Bowel Diseases,
Ulcerative Colitis - Epidemiology, Pathogenesis and Complications, Dr Mortimer O'Connor (Ed.), ISBN: 978-
953-307-880-9, InTech, Available from: http://www.intechopen.com/books/ulcerative-colitis-epidemiology-
pathogenesis-and-complications/kallikrein-kinin-system-and-coagulation-system-in-inflammatory-bowel-
diseases
© 2011 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
